Paper35308532
Favipiravir Effectiveness and Safety in Hospitalized Moderate-Severe COVID-19 Patients: Observational Prospective Multicenter Investigation in Saudi Arabia.
Al-Muhsen S and 10 others. Front Med (Lausanne), 2022. Cited by 7 papers, by iCite.
Cite this record
ConductScience Library. Favipiravir Effectiveness and Safety in Hospitalized Moderate-Severe COVID-19 Patients: Observational Prospective Multicenter Investigation in Saudi Arabia. Papers, record 35308532. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/35308532
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Favipiravir Effectiveness and Safety in Hospitalized Moderate-Severe COVID-19 Patients: Observational Prospective Multicenter Investigation in Saudi Arabia.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References21
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 34699552 | Early administration of remdesivir to COVID-19 patients associates with higher recovery rate and lower need for ICU admission: A retrospective cohort study. | PLoS One | 2021 | https://conductscience.org/library/papers/34699552 | PubMed |
| 2 | 32458459 | Neutrophil to lymphocyte ratio as prognostic and predictive factor in patients with coronavirus disease 2019: A retrospective cross-sectional study. | J Med Virol | 2020 | https://conductscience.org/library/papers/32458459 | PubMed |
| 3 | 33890544 | Effectiveness and safety of favipiravir compared to supportive care in moderately to critically ill COVID-19 patients: a retrospective study with propensity score matching sensitivity analysis. | Curr Med Res Opin | 2021 | https://conductscience.org/library/papers/33890544 | PubMed |
| 4 | 28769016 | Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. | Proc Jpn Acad Ser B Phys Biol Sci | 2017 | https://conductscience.org/library/papers/28769016 | PubMed |
| 5 | 34292670 | Population pharmacokinetics of favipiravir in patients with COVID-19. | CPT Pharmacometrics Syst Pharmacol | 2021 | https://conductscience.org/library/papers/34292670 | PubMed |
| 6 | 34111191 | Combination of (interferon beta-1b, lopinavir/ritonavir and ribavirin) versus favipiravir in hospitalized patients with non-critical COVID-19: A cohort study. | PLoS One | 2021 | https://conductscience.org/library/papers/34111191 | PubMed |
| 7 | 25544306 | Favipiravir: a new medication for the Ebola virus disease pandemic. | Disaster Med Public Health Prep | 2015 | https://conductscience.org/library/papers/25544306 | PubMed |
| 8 | 33882157 | Japan's Drug Regulation During the COVID-19 Pandemic: Lessons From a Case Study of Favipiravir. | Clin Pharmacol Ther | 2022 | https://conductscience.org/library/papers/33882157 | PubMed |
| 9 | 32678530 | Dexamethasone in Hospitalized Patients with Covid-19. | N Engl J Med | 2021 | https://conductscience.org/library/papers/32678530 | PubMed |
| 10 | 33212256 | Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial. | Int J Infect Dis | 2021 | https://conductscience.org/library/papers/33212256 | PubMed |
| 11 | 29882740 | Use of Favipiravir to Treat Lassa Virus Infection in Macaques. | Emerg Infect Dis | 2018 | https://conductscience.org/library/papers/29882740 | PubMed |
| 12 | 34234012 | Drugs repurposed for COVID-19 by virtual screening of 6,218 drugs and cell-based assay. | Proc Natl Acad Sci U S A | 2021 | https://conductscience.org/library/papers/34234012 | PubMed |
| 13 | 34040117 | The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials. | Sci Rep | 2021 | https://conductscience.org/library/papers/34040117 | PubMed |
| 14 | 20122499 | Conclusion about the association between valve surgery and mortality in an infective endocarditis cohort changed after adjusting for survivor bias. | J Clin Epidemiol | 2010 | https://conductscience.org/library/papers/20122499 | PubMed |
| 15 | 34044777 | Favipiravir for the treatment of patients with COVID-19: a systematic review and meta-analysis. | BMC Infect Dis | 2021 | https://conductscience.org/library/papers/34044777 | PubMed |
| 16 | 32979408 | Neutrophil-to-lymphocyte ratio on admission is an independent risk factor for the severity and mortality in patients with coronavirus disease 2019. | J Infect | 2021 | https://conductscience.org/library/papers/32979408 | PubMed |
| 17 | 32346491 | Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study. | Engineering (Beijing) | 2020 | https://conductscience.org/library/papers/32346491 | PubMed |
| 18 | 33741945 | Favipiravir antiviral efficacy against SARS-CoV-2 in a hamster model. | Nat Commun | 2021 | https://conductscience.org/library/papers/33741945 | PubMed |
| 19 | 34319552 | Favipiravir and Hydroxychloroquine Combination Therapy in Patients with Moderate to Severe COVID-19 (FACCT Trial): An Open-Label, Multicenter, Randomized, Controlled Trial. | Infect Dis Ther | 2021 | https://conductscience.org/library/papers/34319552 | PubMed |
| 20 | 34347191 | Effectiveness of favipiravir in COVID-19: a live systematic review. | Eur J Clin Microbiol Infect Dis | 2021 | https://conductscience.org/library/papers/34347191 | PubMed |
Cited by6
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 7 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 40465794 | In-hospital mortality outcomes of favipiravir in patients with moderate to severe COVID-19 infection: An emulated target trial using real-world data from the largest field hospital in Thailand. | PLoS One | 2025 | https://conductscience.org/library/papers/40465794 | PubMed |
| 38770366 | Remdesivir versus Favipiravir in Hospitalized Patients with Moderate to Severe COVID-19 Pneumonia: A Propensity Score-Matched Retrospective Cohort Study. | Int J Gen Med | 2024 | https://conductscience.org/library/papers/38770366 | PubMed |
| 38665565 | Multiple inborn errors of type I IFN immunity in a 33-year-old male with a fatal case of COVID-19. | Heliyon | 2024 | https://conductscience.org/library/papers/38665565 | PubMed |
| 38086763 | Development of iminosugar-based glycosidase inhibitors as drug candidates for SARS-CoV-2 virus via molecular modelling and in vitro studies. | J Enzyme Inhib Med Chem | 2024 | https://conductscience.org/library/papers/38086763 | PubMed |
| 37153358 | Profiles of Independent-Comorbidity Groups in Senior COVID-19 Patients Reveal Low Fatality Associated with Standard Care and Low-Dose Hydroxychloroquine over Antivirals. | J Multidiscip Healthc | 2023 | https://conductscience.org/library/papers/37153358 | PubMed |
| 36271948 | Saliva metabolomic profile of COVID-19 patients associates with disease severity. | Metabolomics | 2022 | https://conductscience.org/library/papers/36271948 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/35308532
GET https://conductscience.org/api/papers/v1/35308532/references?page=2